Virginia F. Borges

Jan 23, 2025 | nature.com | Fresia Pareja |Rohit Bhargava |Virginia F. Borges |Edi Brogi |Fatima Cardoso |Christine Desmedt | +16 more

AbstractSpecial histologic subtypes of breast cancer (BC) exhibit unique phenotypes and molecular profiles with diagnostic and therapeutic implications, often differing in behavior and clinical trajectory from common BC forms. Novel methodologies, such as artificial intelligence may improve classification. Genetic predisposition plays roles in a subset of cases. Uncommon BC presentations like male, inflammatory and pregnancy-related BC pose challenges.

Oct 5, 2024 | nature.com | Anthony Elias |Alyse W. Staley |Monica N. Fornier |Elena Shagisultanova |Rosa I. Gallagher |Jill E. Slansky | +1 more

AbstractMost ER+ breast cancers (BC) express androgen receptors (AR). This randomized phase II trial of 4 months of neoadjuvant fulvestrant (Fulv) alone or with enzalutamide (Combo) assessed whether adding AR blockade to Fulv would limit residual tumor at the time of surgery, as measured by modified preoperative endocrine predictive index (PEPI) score. Eligible patients were women with ER+/HER2− primary BC cT2 or greater. Stratification factors were clinical node and T-stage.

Oct 1, 2024 | nature.com | Ashton C. Berger |Massimo Cristofanilli |Jason A Burdick |Virginia F. Borges

AbstractCollagen plays a critical role in regulating breast cancer progression and therapeutic resistance. An improved understanding of both the features and drivers of tumor-permissive and -restrictive collagen matrices are critical to improve prognostication and develop more effective therapeutic strategies. In this study, using a combination of in vitro, in vivo and bioinformatic experiments, we show that type III collagen (Col3) plays a tumor-restrictive role in human breast cancer.

Sep 26, 2024 | larioja.com | Virginia F. Borges

TribunaEl camino del éxito está en trabajar juntos, en saber sumar y dejar a un lado pequeñeces, en reconocer las buenas ideas y no conformarnos con las otrasVirginia BorgesDirectora General de Turismo y Promoción TerritorialJueves, 26 de septiembre 2024, 21:55Necesitas ser suscriptor para acceder a esta funcionalidad. Hoy celebramos el Día Mundial del Turismo.

Jul 31, 2024 | nature.com | Yue Zheng |Kathryn J. Ruddy |Rulla M Tamimi |Virginia F. Borges

AbstractOvarian function suppression (OFS) benefits young women with hormone receptor (HR)-positive breast cancer but they are at risk for ovarian function breakthrough. We assessed endocrine effects of gonadotropin-releasing hormone agonist (GnRHa) treatment in a prospective cohort of patients aged ≤ 40 years with HR-positive breast cancer. Plasma estradiol (E2), estrone, and follicule-stimulating hormone (FSH) levels were measured from blood samples drawn 1 and 4 years after diagnosis.